Literature DB >> 21326196

Human Ecstasy use is associated with increased cortical excitability: an fMRI study.

Amy L Bauernfeind1, Mary S Dietrich, Jennifer U Blackford, Evonne J Charboneau, James G Lillevig, Christopher J Cannistraci, Neil D Woodward, Aize Cao, Tristan Watkins, Christina R Di Iorio, Carissa Cascio, Ronald M Salomon, Ronald L Cowan.   

Abstract

The serotonergic neurotoxin, 3,4-methylenedioxymethamphetamine (MDMA/Ecstasy), is a highly popular recreational drug. Human recreational MDMA users have neurocognitive and neuropsychiatric impairments, and human neuroimaging data are consistent with animal reports of serotonin neurotoxicity. However, functional neuroimaging studies have not found consistent effects of MDMA on brain neurophysiology in human users. Several lines of evidence suggest that studying MDMA effects in visual system might reveal the general cortical and subcortical neurophysiological consequences of MDMA use. We used 3 T functional magnetic resonance imaging during visual stimulation to compare visual system lateral geniculate nucleus (LGN) and Brodmann Area (BA) 17 and BA 18 activation in 20 long abstinent (479.95±580.65 days) MDMA users and 20 non-MDMA user controls. Lifetime quantity of MDMA use was strongly positively correlated with blood oxygenation level-dependent (BOLD) signal intensity in bilateral LGN (r(s)=0.59; p=0.007), BA 17 (r(s)=0.50; p=0.027), and BA 18 (r(s)=0.48; p=0.031), and with the spatial extent of activation in BA 17 (r(s)=0.059; p=0.007) and BA 18 (r(s)=0.55; p=0.013). There were no between-group differences in brain activation in any region, but the heaviest MDMA users showed a significantly greater spatial extent of activation than controls in BA 17 (p=0.031) and BA 18 (p=0.049). These results suggest that human recreational MDMA use may be associated with a long-lasting increase in cortical excitability, possibly through loss of serotonin input to cortical and subcortical regions. When considered in the context of previous results, cortical hyper-excitability may be a biomarker for MDMA-induced serotonin neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21326196      PMCID: PMC3079831          DOI: 10.1038/npp.2010.244

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  79 in total

1.  The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties.

Authors:  W Fals-Stewart; T J O'Farrell; T T Freitas; S K McFarlin; P Rutigliano
Journal:  J Consult Clin Psychol       Date:  2000-02

2.  Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study.

Authors:  L Chang; C S Grob; T Ernst; L Itti; F S Mishkin; R Jose-Melchor; R E Poland
Journal:  Psychiatry Res       Date:  2000-02-28       Impact factor: 3.222

3.  Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study.

Authors:  John Karageorgiou; Mary S Dietrich; Evonne J Charboneau; Neil D Woodward; Jennifer U Blackford; Ronald M Salomon; Ronald L Cowan
Journal:  Neuroimage       Date:  2009-03-02       Impact factor: 6.556

4.  Serotoninergic fine-tuning of the excitation-inhibition balance in rat visual cortical networks.

Authors:  Alexandre William Moreau; Muriel Amar; Nicolas Le Roux; Nicolas Morel; Philippe Fossier
Journal:  Cereb Cortex       Date:  2009-06-11       Impact factor: 5.357

5.  Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users.

Authors:  D M Semple; K P Ebmeier; M F Glabus; R E O'Carroll; E C Johnstone
Journal:  Br J Psychiatry       Date:  1999-07       Impact factor: 9.319

6.  Sex differences in response to red and blue light in human primary visual cortex: a bold fMRI study.

Authors:  R L Cowan; B B Frederick; M Rainey; J M Levin; L C Maas; J Bang; J Hennen; S E Lukas; P F Renshaw
Journal:  Psychiatry Res       Date:  2000-12-22       Impact factor: 3.222

7.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

8.  Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.

Authors:  Gloria M P Roberts; Liam Nestor; Hugh Garavan
Journal:  Brain Res       Date:  2009-07-23       Impact factor: 3.252

Review 9.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

10.  Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users.

Authors:  Una D McCann; Michael J Wilson; Francis P Sgambati; George A Ricaurte
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

View more
  9 in total

1.  Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Authors:  Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

2.  Methodological weaknesses in non-randomized studies of ecstasy (MDMA) use: a cautionary note to readers and reviewers.

Authors:  Teri S Krebs; Pål-Ørjan Johansen
Journal:  Neuropsychopharmacology       Date:  2012-03       Impact factor: 7.853

Review 3.  Brain serotonin function in MDMA (ecstasy) users: evidence for persisting neurotoxicity.

Authors:  Margaret M Benningfield; Ronald L Cowan
Journal:  Neuropsychopharmacology       Date:  2013-01       Impact factor: 7.853

4.  MDMA (Ecstasy) association with impaired fMRI BOLD thalamic coherence and functional connectivity.

Authors:  Ronald M Salomon; John Karageorgiou; Mary S Dietrich; Jessica Y McLellan; Evonne J Charboneau; Jennifer U Blackford; Ronald L Cowan
Journal:  Drug Alcohol Depend       Date:  2011-07-31       Impact factor: 4.492

5.  Thalamocortical dysconnectivity in autism spectrum disorder: An analysis of the Autism Brain Imaging Data Exchange.

Authors:  Neil D Woodward; Monica Giraldo-Chica; Baxter Rogers; Carissa J Cascio
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-01

6.  Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing.

Authors:  Tristan J Watkins; Vidya Raj; Junghee Lee; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Ronald M Salomon; Sohee Park; Margaret M Benningfield; Christina R Di Iorio; Ronald L Cowan
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

7.  Intrainsular connectivity and somatosensory responsiveness in young children with ASD.

Authors:  Michelle D Failla; Brittany R Peters; Haleh Karbasforoushan; Jennifer H Foss-Feig; Kimberly B Schauder; Brynna H Heflin; Carissa J Cascio
Journal:  Mol Autism       Date:  2017-06-13       Impact factor: 7.509

8.  Thalamocortical connectivity is associated with autism symptoms in high-functioning adults with autism and typically developing adults.

Authors:  Manish Saggar; Lawrence K Fung; Rafi Ayub; Kevin L Sun; Ryan E Flores; Vicky T Lam; Booil Jo
Journal:  Transl Psychiatry       Date:  2021-02-03       Impact factor: 6.222

Review 9.  Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Authors:  Giulia Costa; Maria Antonietta De Luca; Gessica Piras; Jacopo Marongiu; Liana Fattore; Nicola Simola
Journal:  Neural Regen Res       Date:  2020-05       Impact factor: 5.135

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.